Workflow
Development
icon
Search documents
X @BSCN
BSCN 2025-09-04 04:20
RT BSCN (@BSCNews)馃敟 $ICP DEVELOPMENT IS ON FIRE!! @dfinity's Internet Computer has seen a resurgence in developer interest and the long-term impact could be huge... Catch up now 猬囷笍https://t.co/E9g5U20qxp ...
X @CoinMarketCap
CoinMarketCap 2025-09-04 03:00
馃毃 CMC News: Ethereum Foundation Sells 10,000 $ETH for Development.馃敆 https://t.co/vZTCFWOnEw https://t.co/3aoxh9Caeg ...
X @BSCN
BSCN 2025-09-04 01:18
馃敟 $ICP DEVELOPMENT IS ON FIRE!! @dfinity's Internet Computer has seen a resurgence in developer interest and the long-term impact could be huge... Catch up now 猬囷笍https://t.co/E9g5U20qxp ...
Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL
Globenewswire 2025-08-28 10:07
Core Insights - Sai Life Sciences Limited has completed Phase II of its new Production Block (PB-11) at its API manufacturing facility in Bidar, India, enhancing its production capabilities [1][2]. Expansion Details - Phase I of PB-11, inaugurated in December 2024, had a capacity of 110 KL, and with the addition of Phase II (~91 KL), the total capacity of PB-11 now stands at approximately 200 KL, making it the largest reactor volume block at the Bidar site [2]. - The total installed reactor capacity at the Bidar facility has increased to around 700 KL following this expansion [2][7]. Strategic Importance - The CEO of Sai Life Sciences emphasized that this expansion is not just about increasing capacity but also about providing clients with the confidence to scale operations, ensuring reliable delivery, and adapting to the complexity of their programs [3]. - The PB-11 block is designed for large-scale commercial products, reinforcing the company's commitment to high-quality API and intermediate manufacturing for regulated markets such as the US, EU, and Japan [3]. Regulatory Compliance - The Bidar facility has been inspected and approved by major global regulatory agencies, including the USFDA, PMDA (Japan), and CDSCO (India), demonstrating the company's commitment to quality and compliance [3]. - Over the past three years, Sai Life Sciences has successfully undergone more than 75 customer audits, reflecting its dedication to safety and quality standards [3]. Company Overview - Sai Life Sciences is a leading integrated CRDMO, collaborating with over 300 global pharma and biotech companies to accelerate the development of new chemical entities (NCE) [4]. - The company has a workforce of over 3,400 employees across its facilities in India, the UK, and the USA [4].
X @Bloomberg
Bloomberg 2025-07-26 04:42
The World Bank's approach to funding a $5 billion dam in central Mozambique embodies its new approach to development https://t.co/F9p0GSCDQh ...
X @BNB Chain
BNB Chain 2025-07-25 15:00
Software Development Lifecycle - The document outlines a repetitive software development lifecycle: build, test, deploy, sleep, on repeat [1] Industry Focus - The industry focuses on continuous iteration and automation in software development [1]
X @Bloomberg
Bloomberg 2025-07-21 06:48
President Prabowo Subianto launched the first of thousands of planned new community cooperatives, betting on a top-down approach and billions of dollars in loans from Indonesia鈥檚 state banks to spur development and food self-sufficiency https://t.co/oC0T7WNhHz ...
X @BSCN
BSCN 2025-07-19 21:11
RT BSCN (@BSCNews)DEVELOPMENT ON $ICP IS SURGING! This year could be huge for @dfinity's Internet Computer... Here's why https://t.co/E9g5U20qxp ...
X @BSCN
BSCN 2025-07-19 17:11
RT BSCN (@BSCNews)DEVELOPMENT ON $ICP IS SURGING! This year could be huge for @dfinity's Internet Computer... Here's why https://t.co/E9g5U20qxp ...